Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
The scientific collaboration includes the Company’s lead product candidate istaroxime and the next generation compounds called SERCA2a activators.
- The scientific collaboration includes the Company’s lead product candidate istaroxime and the next generation compounds called SERCA2a activators.
- SERCA2a activity is decreased in heart failure and disordered calcium handling can play a role in cardiac arrythmias.
- Windtree believes activation of SERCA2a could represent an important advancement in heart failure treatment for patients.
- Outside of this scientific collaboration, istaroxime is being studied in the Phase 2 SEISMiC Extension Study in early cardiogenic shock.